MT-601 T Cell Therapy for Relapsed Non-Hodgkin Lymphoma
Official title: A Phase 1 Study of Patient-Derived Multi-Tumor-Associated Antigen Specific T Cells (MT-601) Administered to Patients with Relapsed Non-Hodgkin Lymphoma
Funded at Marker Therapeutics, INC. · NIH-11164733 · Data updated 2026-11-12
This opportunity explores a new T cell therapy called MT-601 for people with Non-Hodgkin Lymphoma that has returned after previous treatments.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Marker Therapeutics, INC. NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project start | August 1, 2024 |
| Project end | July 31, 2027 |
| Funding year | 2025 |
| Award (this year) | $665,000 |
| NIH project number | 5R44CA291521-02 |
| Project ID | NIH-11164733 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are patients with Non-Hodgkin Lymphoma whose cancer has returned after receiving prior CAR T cell therapy or other treatments.
✕Less likely to help
Patients whose Non-Hodgkin Lymphoma has not relapsed or who have not received prior CAR T cell therapy may not be suitable for this specific treatment approach.
What this research studies
This therapy, MT-601, is a new type of immunotherapy that uses your own immune cells to fight cancer. We collect your T cells and train them to recognize six specific markers found on lymphoma cells, but not on healthy cells. These specially prepared T cells are then given back to you to target and destroy the cancer cells. The goal is to create a stronger and more lasting anti-tumor response while potentially reducing severe side effects seen with other T cell therapies.
Why it matters
Potential benefit: If successful, this therapy could offer a new treatment option for Non-Hodgkin Lymphoma patients who have relapsed after other T cell therapies, potentially leading to better outcomes and fewer side effects.
How similar studies have gone: While CAR T cell therapies have shown impressive results in NHL, this approach is novel in targeting multiple tumor antigens simultaneously to address relapse after CAR T therapy.
Where this research is happening
-
Marker Therapeutics, INC.
Houston, United States Active
Researchers
- Principal investigator: Vera, Juan Fernando — Marker Therapeutics, INC.
- Study coordinator: Vera, Juan Fernando
Related research
Other NIH-funded projects on the same topics.
-
Multi-antigen T cell therapy for relapsed NHL
A patient-derived T cell therapy called MT-601 targets six tumor-associated antigens to help treat relapsed non-Hodgkin lymphoma after other therapies may have failed.
-
New T cell therapy for patients with relapsed Non-Hodgkin Lymphoma
This study is testing a new treatment for people with relapsed Non-Hodgkin Lymphoma that uses their own immune cells to better fight cancer by targeting multiple markers on the cancer cells, with the hope of making the treatment more effective and lowering the risk of the cancer coming back.
-
Novel combination therapy for non-Hodgkin lymphoma in people and dogs
A new treatment combo using an oncolytic virus and other therapies is being tested to help people with hard-to-treat non-Hodgkin lymphoma, with studies also involving dogs to better understand responses.
-
Combination therapy approach for non-Hodgkin lymphoma (NHL)
A Mayo Clinic team is testing a new combination treatment for non-Hodgkin lymphoma to improve responses in patients and in dogs with similar disease.
-
Precision targeted radioactive antibody therapy for non-Hodgkin lymphoma
Researchers are developing more precise radioactive antibodies to treat people with CD20-positive non-Hodgkin lymphoma.
-
AI-designed drugs targeting a common lymphoma mutation (MYD88 L265P)
Researchers are using artificial intelligence to create and test new drugs that block a common MYD88 mutation found in many B‑cell non‑Hodgkin lymphomas to help people with these cancers.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.